A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model

BACKGROUND Castration results in a major involution of the normal prostate gland. This process is initiated by effects in the prostate stroma and vasculature. Castration‐induced regression of androgen sensitive prostate tumors is however less prominent and hypothetically this could be related to a l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Prostate 2007-11, Vol.67 (15), p.1664-1676
Hauptverfasser: Johansson, Anna, Jones, Jonathan, Pietras, Kristian, Kilter, Sigrid, Skytt, Åsa, Rudolfsson, Stina Häggström, Bergh, Anders
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1676
container_issue 15
container_start_page 1664
container_title The Prostate
container_volume 67
creator Johansson, Anna
Jones, Jonathan
Pietras, Kristian
Kilter, Sigrid
Skytt, Åsa
Rudolfsson, Stina Häggström
Bergh, Anders
description BACKGROUND Castration results in a major involution of the normal prostate gland. This process is initiated by effects in the prostate stroma and vasculature. Castration‐induced regression of androgen sensitive prostate tumors is however less prominent and hypothetically this could be related to a limited stromal/vascular response. We therefore used animal tumor models to explore the importance of stroma and vascular effects, and if castration effects could be enhanced by a simultaneous therapy targeting the tumor stroma. METHODS Using rats with Dunning PAP and H tumors, stereological methods, immunohistochemistry, and Western blotting, we studied the tumor response 7 and 28 days after castration and after the addition of stroma targeted therapies. RESULTS In the normal ventral prostate (VP) nuclear androgen receptors (AR) were rapidly downregulated after castration. In contrast, the Dunning tumors downregulated the AR in the cancerous epithelium, but not in the surrounding stroma. Vascular regulators such as the angiopoietins, tie 2, and PDGF‐Rβ were not decreased in the stroma after castration, as observed in the VP, creating an environment that prevents vascular involution. When a tumor stroma targeted therapy inhibiting the tie 2 receptor and the PDGF‐Rβ simultaneously was added to castration it resulted in a decreased vascular density, increased tumor cell apoptosis and decreased tumor growth compared to castration alone. CONCLUSIONS The stroma in highly differentiated androgen sensitive Dunning tumors is apparently androgen insensitive. If this unresponsive stroma is targeted the effects of castration can be enhanced. Prostate 67: 1664–1676, 2007. © 2007 Wiley‐Liss, Inc.
doi_str_mv 10.1002/pros.20657
format Article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_568293</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68319495</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4707-fe0e3b50e3950354594c981393b945fc4f2659bc11b2f4d388a8a9f859c61633</originalsourceid><addsrcrecordid>eNp90U9vFCEUAHBiNHatXvwAhos9GKfCAAMcN6tWk41t7EaNF8Kwj3bs_BOY1P32su7YnvQChPzee_AeQs8pOaWElG_GMMTTklRCPkALSrQsCOHiIVqQUpKCUyaP0JMYfxCSOSkfoyMqleBEqAVySxxTGDqLkw1XkGCL0zUEO-4w9Ne2dxCxs5nY1Aw9Bu_BpYibHueIYPs4trZPtm4BZ4L3T0k2QY7JoQF3wxbap-iRt22EZ_N-jDbv321WH4r1-dnH1XJdOC6JLDwQYLXIixaECS40d1pRplmtufCO-7ISunaU1qXnW6aUVVZ7JbSraMXYMSoOaeMtjFNtxtB0NuzMYBszX93kExhRqVLv_et_-rfNl6UZwpWZusmUJRU685MDz3_8OUFMpmuigzb_H4YpmkoxqrkWGb46QJebEQP4u8yUmP3AzL5L5s_AMn4xZ53qDrb3dJ5QBi9nYKOzrc89d028d5pypRXPjh7cbdPC7j8lzcXn88u_xeeONTHBr7sYG25MJZkU5uunM7NaX8jvm2-XZsV-A3UKvnw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68319495</pqid></control><display><type>article</type><title>A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Johansson, Anna ; Jones, Jonathan ; Pietras, Kristian ; Kilter, Sigrid ; Skytt, Åsa ; Rudolfsson, Stina Häggström ; Bergh, Anders</creator><creatorcontrib>Johansson, Anna ; Jones, Jonathan ; Pietras, Kristian ; Kilter, Sigrid ; Skytt, Åsa ; Rudolfsson, Stina Häggström ; Bergh, Anders</creatorcontrib><description>BACKGROUND Castration results in a major involution of the normal prostate gland. This process is initiated by effects in the prostate stroma and vasculature. Castration‐induced regression of androgen sensitive prostate tumors is however less prominent and hypothetically this could be related to a limited stromal/vascular response. We therefore used animal tumor models to explore the importance of stroma and vascular effects, and if castration effects could be enhanced by a simultaneous therapy targeting the tumor stroma. METHODS Using rats with Dunning PAP and H tumors, stereological methods, immunohistochemistry, and Western blotting, we studied the tumor response 7 and 28 days after castration and after the addition of stroma targeted therapies. RESULTS In the normal ventral prostate (VP) nuclear androgen receptors (AR) were rapidly downregulated after castration. In contrast, the Dunning tumors downregulated the AR in the cancerous epithelium, but not in the surrounding stroma. Vascular regulators such as the angiopoietins, tie 2, and PDGF‐Rβ were not decreased in the stroma after castration, as observed in the VP, creating an environment that prevents vascular involution. When a tumor stroma targeted therapy inhibiting the tie 2 receptor and the PDGF‐Rβ simultaneously was added to castration it resulted in a decreased vascular density, increased tumor cell apoptosis and decreased tumor growth compared to castration alone. CONCLUSIONS The stroma in highly differentiated androgen sensitive Dunning tumors is apparently androgen insensitive. If this unresponsive stroma is targeted the effects of castration can be enhanced. Prostate 67: 1664–1676, 2007. © 2007 Wiley‐Liss, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>ISSN: 1097-0045</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.20657</identifier><identifier>PMID: 17854058</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - metabolism ; Adenocarcinoma - pathology ; Androgen Receptor Antagonists ; androgens ; angiopoietins ; Angiopoietins - antagonists &amp; inhibitors ; Angiopoietins - metabolism ; Animals ; Antineoplastic Agents - pharmacology ; Benzamides ; Biological and medical sciences ; Disease Models, Animal ; Down-Regulation ; Drug Therapy, Combination ; Gynecology. Andrology. Obstetrics ; Imatinib Mesylate ; Immunoglobulin Fc Fragments - pharmacology ; Male ; Male genital diseases ; Medical sciences ; Neoplasm Transplantation ; Neovascularization, Pathologic - pathology ; Neovascularization, Pathologic - prevention &amp; control ; Nephrology. Urinary tract diseases ; Orchiectomy ; PDGF-Rβ ; Piperazines - pharmacology ; prostate ; Prostate - blood supply ; Prostate - drug effects ; Prostate - metabolism ; Prostate - pathology ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - metabolism ; Prostatic Neoplasms - pathology ; Pyrimidines - pharmacology ; Rats ; Receptor, Platelet-Derived Growth Factor beta - antagonists &amp; inhibitors ; Receptor, Platelet-Derived Growth Factor beta - metabolism ; Receptor, TIE-2 - antagonists &amp; inhibitors ; Receptor, TIE-2 - immunology ; Receptor, TIE-2 - metabolism ; Receptors, Androgen - metabolism ; Recombinant Fusion Proteins - pharmacology ; stroma ; Stromal Cells - drug effects ; Stromal Cells - metabolism ; Stromal Cells - pathology ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland ; Xenograft Model Antitumor Assays</subject><ispartof>The Prostate, 2007-11, Vol.67 (15), p.1664-1676</ispartof><rights>Copyright © 2007 Wiley‐Liss, Inc.</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4707-fe0e3b50e3950354594c981393b945fc4f2659bc11b2f4d388a8a9f859c61633</citedby><cites>FETCH-LOGICAL-c4707-fe0e3b50e3950354594c981393b945fc4f2659bc11b2f4d388a8a9f859c61633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpros.20657$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpros.20657$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19148984$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17854058$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-22159$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:116126518$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Johansson, Anna</creatorcontrib><creatorcontrib>Jones, Jonathan</creatorcontrib><creatorcontrib>Pietras, Kristian</creatorcontrib><creatorcontrib>Kilter, Sigrid</creatorcontrib><creatorcontrib>Skytt, Åsa</creatorcontrib><creatorcontrib>Rudolfsson, Stina Häggström</creatorcontrib><creatorcontrib>Bergh, Anders</creatorcontrib><title>A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>BACKGROUND Castration results in a major involution of the normal prostate gland. This process is initiated by effects in the prostate stroma and vasculature. Castration‐induced regression of androgen sensitive prostate tumors is however less prominent and hypothetically this could be related to a limited stromal/vascular response. We therefore used animal tumor models to explore the importance of stroma and vascular effects, and if castration effects could be enhanced by a simultaneous therapy targeting the tumor stroma. METHODS Using rats with Dunning PAP and H tumors, stereological methods, immunohistochemistry, and Western blotting, we studied the tumor response 7 and 28 days after castration and after the addition of stroma targeted therapies. RESULTS In the normal ventral prostate (VP) nuclear androgen receptors (AR) were rapidly downregulated after castration. In contrast, the Dunning tumors downregulated the AR in the cancerous epithelium, but not in the surrounding stroma. Vascular regulators such as the angiopoietins, tie 2, and PDGF‐Rβ were not decreased in the stroma after castration, as observed in the VP, creating an environment that prevents vascular involution. When a tumor stroma targeted therapy inhibiting the tie 2 receptor and the PDGF‐Rβ simultaneously was added to castration it resulted in a decreased vascular density, increased tumor cell apoptosis and decreased tumor growth compared to castration alone. CONCLUSIONS The stroma in highly differentiated androgen sensitive Dunning tumors is apparently androgen insensitive. If this unresponsive stroma is targeted the effects of castration can be enhanced. Prostate 67: 1664–1676, 2007. © 2007 Wiley‐Liss, Inc.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - metabolism</subject><subject>Adenocarcinoma - pathology</subject><subject>Androgen Receptor Antagonists</subject><subject>androgens</subject><subject>angiopoietins</subject><subject>Angiopoietins - antagonists &amp; inhibitors</subject><subject>Angiopoietins - metabolism</subject><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Benzamides</subject><subject>Biological and medical sciences</subject><subject>Disease Models, Animal</subject><subject>Down-Regulation</subject><subject>Drug Therapy, Combination</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Imatinib Mesylate</subject><subject>Immunoglobulin Fc Fragments - pharmacology</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Neoplasm Transplantation</subject><subject>Neovascularization, Pathologic - pathology</subject><subject>Neovascularization, Pathologic - prevention &amp; control</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Orchiectomy</subject><subject>PDGF-Rβ</subject><subject>Piperazines - pharmacology</subject><subject>prostate</subject><subject>Prostate - blood supply</subject><subject>Prostate - drug effects</subject><subject>Prostate - metabolism</subject><subject>Prostate - pathology</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Pyrimidines - pharmacology</subject><subject>Rats</subject><subject>Receptor, Platelet-Derived Growth Factor beta - antagonists &amp; inhibitors</subject><subject>Receptor, Platelet-Derived Growth Factor beta - metabolism</subject><subject>Receptor, TIE-2 - antagonists &amp; inhibitors</subject><subject>Receptor, TIE-2 - immunology</subject><subject>Receptor, TIE-2 - metabolism</subject><subject>Receptors, Androgen - metabolism</subject><subject>Recombinant Fusion Proteins - pharmacology</subject><subject>stroma</subject><subject>Stromal Cells - drug effects</subject><subject>Stromal Cells - metabolism</subject><subject>Stromal Cells - pathology</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0270-4137</issn><issn>1097-0045</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90U9vFCEUAHBiNHatXvwAhos9GKfCAAMcN6tWk41t7EaNF8Kwj3bs_BOY1P32su7YnvQChPzee_AeQs8pOaWElG_GMMTTklRCPkALSrQsCOHiIVqQUpKCUyaP0JMYfxCSOSkfoyMqleBEqAVySxxTGDqLkw1XkGCL0zUEO-4w9Ne2dxCxs5nY1Aw9Bu_BpYibHueIYPs4trZPtm4BZ4L3T0k2QY7JoQF3wxbap-iRt22EZ_N-jDbv321WH4r1-dnH1XJdOC6JLDwQYLXIixaECS40d1pRplmtufCO-7ISunaU1qXnW6aUVVZ7JbSraMXYMSoOaeMtjFNtxtB0NuzMYBszX93kExhRqVLv_et_-rfNl6UZwpWZusmUJRU685MDz3_8OUFMpmuigzb_H4YpmkoxqrkWGb46QJebEQP4u8yUmP3AzL5L5s_AMn4xZ53qDrb3dJ5QBi9nYKOzrc89d028d5pypRXPjh7cbdPC7j8lzcXn88u_xeeONTHBr7sYG25MJZkU5uunM7NaX8jvm2-XZsV-A3UKvnw</recordid><startdate>20071101</startdate><enddate>20071101</enddate><creator>Johansson, Anna</creator><creator>Jones, Jonathan</creator><creator>Pietras, Kristian</creator><creator>Kilter, Sigrid</creator><creator>Skytt, Åsa</creator><creator>Rudolfsson, Stina Häggström</creator><creator>Bergh, Anders</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D93</scope></search><sort><creationdate>20071101</creationdate><title>A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model</title><author>Johansson, Anna ; Jones, Jonathan ; Pietras, Kristian ; Kilter, Sigrid ; Skytt, Åsa ; Rudolfsson, Stina Häggström ; Bergh, Anders</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4707-fe0e3b50e3950354594c981393b945fc4f2659bc11b2f4d388a8a9f859c61633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - metabolism</topic><topic>Adenocarcinoma - pathology</topic><topic>Androgen Receptor Antagonists</topic><topic>androgens</topic><topic>angiopoietins</topic><topic>Angiopoietins - antagonists &amp; inhibitors</topic><topic>Angiopoietins - metabolism</topic><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Benzamides</topic><topic>Biological and medical sciences</topic><topic>Disease Models, Animal</topic><topic>Down-Regulation</topic><topic>Drug Therapy, Combination</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Imatinib Mesylate</topic><topic>Immunoglobulin Fc Fragments - pharmacology</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Neoplasm Transplantation</topic><topic>Neovascularization, Pathologic - pathology</topic><topic>Neovascularization, Pathologic - prevention &amp; control</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Orchiectomy</topic><topic>PDGF-Rβ</topic><topic>Piperazines - pharmacology</topic><topic>prostate</topic><topic>Prostate - blood supply</topic><topic>Prostate - drug effects</topic><topic>Prostate - metabolism</topic><topic>Prostate - pathology</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Pyrimidines - pharmacology</topic><topic>Rats</topic><topic>Receptor, Platelet-Derived Growth Factor beta - antagonists &amp; inhibitors</topic><topic>Receptor, Platelet-Derived Growth Factor beta - metabolism</topic><topic>Receptor, TIE-2 - antagonists &amp; inhibitors</topic><topic>Receptor, TIE-2 - immunology</topic><topic>Receptor, TIE-2 - metabolism</topic><topic>Receptors, Androgen - metabolism</topic><topic>Recombinant Fusion Proteins - pharmacology</topic><topic>stroma</topic><topic>Stromal Cells - drug effects</topic><topic>Stromal Cells - metabolism</topic><topic>Stromal Cells - pathology</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Johansson, Anna</creatorcontrib><creatorcontrib>Jones, Jonathan</creatorcontrib><creatorcontrib>Pietras, Kristian</creatorcontrib><creatorcontrib>Kilter, Sigrid</creatorcontrib><creatorcontrib>Skytt, Åsa</creatorcontrib><creatorcontrib>Rudolfsson, Stina Häggström</creatorcontrib><creatorcontrib>Bergh, Anders</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Umeå universitet</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Johansson, Anna</au><au>Jones, Jonathan</au><au>Pietras, Kristian</au><au>Kilter, Sigrid</au><au>Skytt, Åsa</au><au>Rudolfsson, Stina Häggström</au><au>Bergh, Anders</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2007-11-01</date><risdate>2007</risdate><volume>67</volume><issue>15</issue><spage>1664</spage><epage>1676</epage><pages>1664-1676</pages><issn>0270-4137</issn><issn>1097-0045</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>BACKGROUND Castration results in a major involution of the normal prostate gland. This process is initiated by effects in the prostate stroma and vasculature. Castration‐induced regression of androgen sensitive prostate tumors is however less prominent and hypothetically this could be related to a limited stromal/vascular response. We therefore used animal tumor models to explore the importance of stroma and vascular effects, and if castration effects could be enhanced by a simultaneous therapy targeting the tumor stroma. METHODS Using rats with Dunning PAP and H tumors, stereological methods, immunohistochemistry, and Western blotting, we studied the tumor response 7 and 28 days after castration and after the addition of stroma targeted therapies. RESULTS In the normal ventral prostate (VP) nuclear androgen receptors (AR) were rapidly downregulated after castration. In contrast, the Dunning tumors downregulated the AR in the cancerous epithelium, but not in the surrounding stroma. Vascular regulators such as the angiopoietins, tie 2, and PDGF‐Rβ were not decreased in the stroma after castration, as observed in the VP, creating an environment that prevents vascular involution. When a tumor stroma targeted therapy inhibiting the tie 2 receptor and the PDGF‐Rβ simultaneously was added to castration it resulted in a decreased vascular density, increased tumor cell apoptosis and decreased tumor growth compared to castration alone. CONCLUSIONS The stroma in highly differentiated androgen sensitive Dunning tumors is apparently androgen insensitive. If this unresponsive stroma is targeted the effects of castration can be enhanced. Prostate 67: 1664–1676, 2007. © 2007 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>17854058</pmid><doi>10.1002/pros.20657</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0270-4137
ispartof The Prostate, 2007-11, Vol.67 (15), p.1664-1676
issn 0270-4137
1097-0045
1097-0045
language eng
recordid cdi_swepub_primary_oai_swepub_ki_se_568293
source MEDLINE; Wiley Online Library All Journals
subjects Adenocarcinoma - drug therapy
Adenocarcinoma - metabolism
Adenocarcinoma - pathology
Androgen Receptor Antagonists
androgens
angiopoietins
Angiopoietins - antagonists & inhibitors
Angiopoietins - metabolism
Animals
Antineoplastic Agents - pharmacology
Benzamides
Biological and medical sciences
Disease Models, Animal
Down-Regulation
Drug Therapy, Combination
Gynecology. Andrology. Obstetrics
Imatinib Mesylate
Immunoglobulin Fc Fragments - pharmacology
Male
Male genital diseases
Medical sciences
Neoplasm Transplantation
Neovascularization, Pathologic - pathology
Neovascularization, Pathologic - prevention & control
Nephrology. Urinary tract diseases
Orchiectomy
PDGF-Rβ
Piperazines - pharmacology
prostate
Prostate - blood supply
Prostate - drug effects
Prostate - metabolism
Prostate - pathology
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - pathology
Pyrimidines - pharmacology
Rats
Receptor, Platelet-Derived Growth Factor beta - antagonists & inhibitors
Receptor, Platelet-Derived Growth Factor beta - metabolism
Receptor, TIE-2 - antagonists & inhibitors
Receptor, TIE-2 - immunology
Receptor, TIE-2 - metabolism
Receptors, Androgen - metabolism
Recombinant Fusion Proteins - pharmacology
stroma
Stromal Cells - drug effects
Stromal Cells - metabolism
Stromal Cells - pathology
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Xenograft Model Antitumor Assays
title A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T01%3A27%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20stroma%20targeted%20therapy%20enhances%20castration%20effects%20in%20a%20transplantable%20rat%20prostate%20cancer%20model&rft.jtitle=The%20Prostate&rft.au=Johansson,%20Anna&rft.date=2007-11-01&rft.volume=67&rft.issue=15&rft.spage=1664&rft.epage=1676&rft.pages=1664-1676&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/pros.20657&rft_dat=%3Cproquest_swepu%3E68319495%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68319495&rft_id=info:pmid/17854058&rfr_iscdi=true